Cover Image

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis

Saved in:

Bibliographic Details
Main Authors:	Annunziata Dattola (Author), Arianna Zangrilli (Author), Luca Bianchi (Author)
Format:	Book
Published:	Mattioli1885, 2021-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
by: Giacomo Caldarola, et al.
Published: (2023)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
by: Reddy V, et al.
Published: (2020)

Anti-programmed cell death-1-induced plaque and guttate psoriasis
by: Toshiyuki Yamamoto
Published: (2018)

Serum Levels of LL-37 and Inflammatory Cytokines in Plaque and Guttate Psoriasis
by: Young Ji Hwang, et al.
Published: (2014)

Hansen's disease with lepra reaction presenting with IgA dominant infection related glomerulonephritis
by: Elayaperumal Indhumathi, et al.
Published: (2020)

Clinicopathologic features of infection-related glomerulonephritis with IgA deposits: a French Nationwide study
by: Elodie Miquelestorena-Standley, et al.
Published: (2020)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018)

Childhood guttate psoriasis: an updated review
by: Alexander KC Leung, et al.
Published: (2023)

Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
by: Diego Orsini, et al.
Published: (2024)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024)

Management of guttate psoriasis in patients with associated streptococcal infection
by: Karabudak Abuaf O, et al.
Published: (2012)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023)

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
by: Gönülal M, et al.
Published: (2023)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017)

Dermoscopy Differentiates Guttate Psoriasis From a Mimicker-Pityriasis Rosea
by: Meena Makhecha, et al.
Published: (2021)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023)

IgA pemphigus showing IgA antibodies to desmoglein 1 and 3
by: Salama Hegazy, et al.
Published: (2016)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023)

A Guttate Psoriasis That Tends to Spare Three Tattoos: A Macrophage Liaison
by: Panagiota Spyridonos, et al.
Published: (2021)

Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients
by: Petr Kosztyu, et al.
Published: (2018)

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
by: Diego Orsini, et al.
Published: (2023)

Analysis of microbial flora in skin lesions of primary acute guttate psoriasis
by: Jia ZHANG, et al.
Published: (2022)

Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy
by: Kai Zhang, et al.
Published: (2019)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
by: Kanako Tsunoda, MD, PhD, et al.
Published: (2024)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
by: Al Muqrin AM, et al.
Published: (2022)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024)

Role of Human Mesangial-Tubular Crosstalk in Secretory IgA-Induced IgA Nephropathy
by: Junjun Zhang, et al.
Published: (2021)

Sulodexide in IgA nephropathy
Published: (2013)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022)

New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette-Guerin
by: Chih-Tsung Hung, et al.
Published: (2012)

Salivary IgA and IgE levels in healthy subjects: relation to age and gender
by: Abdollah Jafarzadeh, et al.
Published: (2010)

Linear IgA and IgG bullous dermatosis
by: Karina de Almeida Pinto Fernandes, et al.
Published: (2016)

Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus
by: Adriana Maria Porro, et al.
Published: (2014)

Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children
by: Yan Lv, et al.
Published: (2023)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
by: Cara Barber, MD, MPH, et al.
Published: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
by: Cara Barber, MD, MPH, et al.
Published: (2022)